RxDoctor Payments Data

Todd Orszulak, DO

Internal Medicine · Niagara Falls, NYNPI 1881761864

Payments from drug & device makers

$9,008in general payments, 2019–2025

Across 472 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$928
  • AbbVie$907
  • GSK$527
  • AstraZeneca$493
  • Astellas Pharma US Inc$468
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$8,57295%
  • Education$4365%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,008 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$12,863
Medicare patients
46
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$54,033
TrulicityDulaglutide27$51,533
EntrestoSacubitril/Valsartan18$28,196
EliquisApixaban26$26,640
MounjaroTirzepatide13$20,352
FarxigaDapagliflozin Propanediol25$18,493
XareltoRivaroxaban13$14,293
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,408
MyrbetriqMirabegron18$10,433
Breo ElliptaFluticasone/Vilanterol21$8,782
Icosapent Ethyl13$3,850
Rosuvastatin Calcium136$2,301
Ezetimibe56$1,546
SynthroidLevothyroxine Sodium18$1,508
Colchicine18$1,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,379$71,88540 claims
Boehringer IngelheimJardiance$928$54,03340 claims
NovartisEntresto$248$28,19618 claims
PfizerEliquis$438$26,64026 claims
GSKTrelegy Ellipta, Breo Ellipta$527$20,19138 claims
AstraZenecaFarxiga$493$18,49325 claims
Johnson & JohnsonXarelto$201$14,29313 claims
Astellas Pharma US IncMyrbetriq$468$10,43318 claims
AbbVieSynthroid$907$1,50818 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$50$53225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Niagara Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →